Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation (ML20981)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00874419 |
Recruitment Status :
Completed
First Posted : April 2, 2009
Last Update Posted : September 25, 2014
|
Sponsor:
Tongji University
Collaborators:
Sun Yat-sen University
Shanghai Chest Hospital
RenJi Hospital
Guangdong Provincial People's Hospital
Peking Union Medical College Hospital
Information provided by (Responsible Party):
Caicun Zhou, Tongji University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | July 2010 |
Actual Study Completion Date : | July 2012 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):